Guardant Health Inc. announced a new partnership with COTA Inc., a leader in real-world data and analytics for oncology. This collaboration will provide biopharmaceutical researchers access to combined resources of COTA’s electronic health record data and Guardant’s clinicogenomic testing data.
The extensive dataset and AI analytics from this partnership will allow research scientists to better understand correlations between molecular biomarkers, treatment decisions, and clinical outcomes. This aims to accelerate the development of new cancer therapies.
Craig Eagle, MD, Guardant Health chief medical officer, stated that this partnership marks another milestone in the company's mission to conquer cancer with data. It will expedite the discovery of new biomarker-based therapies and make the drug development process more economical.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.